Tara Morgan^1,*, Brian Calio¹, Rafael Tua Caraccia¹, Daniel Segal², Joshua Kim³, Sarah Attia⁴, Neil B. Desai⁵, Jeffery Gahan¹

Canadian Journal of Urology, Vol.32, No.4, pp. 309-315, 2025, DOI:10.32604/cju.2025.063408 - 29 August 2025

Abstract Background: Radical prostatectomy has long been the treatment of choice for men with clinically significant prostate cancer (PCa) in those with concurrent significant lower urinary tract symptoms (LUTS). For men who meet this description with marked prostatomegaly, we present a multi-institutional proof of concept study describing an alternative pathway of robotic simple prostatectomy (RASP) followed by external beam radiation therapy (EBRT) for the treatment of clinically significant prostate cancer. Methods: A retrospective study was performed of 17 patients with PCa who underwent RASP followed by EBRT at two institutions from 2015–2023. Demographic, peri-operative, and post-radiation… More >

DEMEI FENG^1,#, SHENRUI BAI^1,#, GUANJUN CHEN¹, BIBO FU¹, CAILU SONG¹, HAILIN TANG¹, LIANG WANG^2,*, HUA WANG^1,*

Oncology Research, Vol.33, No.4, pp. 965-974, 2025, DOI:10.32604/or.2024.057065 - 19 March 2025

Abstract Objectives: The optimal treatment strategy for early-stage natural killer/T-cell lymphoma (NKTCL) remains unclear. This study aimed to evaluate and compare the clinical outcomes and adverse events (AEs) associated with two treatment regimens for early-stage NKTCL: pegaspargase with concurrent radiation therapy (P+CCRT) and pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) with sequential radiation therapy (SERT). Propensity score matching (PSM) was employed to ensure balanced comparison between these regimens. Methods: We assessed the efficacy of P+CCRT from a phase II trial and P-GEMOX combined with SERT using real-world data. PSM was conducted at a 1:1 ratio with a caliper… More >

SHUANG CHEN^1,2,#, XUEMEI DENG^2,#, XINGTING HE², KEWEI XIANG², GUIHONG CHEN², HONGRU YANG^2,*

Oncology Research, Vol.33, No.3, pp. 687-694, 2025, DOI:10.32604/or.2024.052133 - 28 February 2025

Abstract Background: Previous experiments have demonstrated that hypofractionated radiation therapy (HFRT), low-dose radiation therapy (LDRT), and combined anti-programmed cell death protein 1 (αPD-1) can enhance the abscopal effect. Combined with the phenomenon of low prognosis in patients with breast cancer lung metastasis, our study establishes a mouse model and changes the irradiation regimen of LDRT to explore its preventive effect on breast cancer lung metastasis. Methods: The breast cancer subcutaneous graft tumor model was developed. Two-lung prophylactic LDRT was performed prior to the onset of lung metastases, in combination with HFRT (8 Gy, 3f), and αPD-1… More >

JEN-PIN CHUANG^1,2,3, HSIANG-LIN TSAI^4,5, WEI-CHIH SU^4,6,7, PO-JUNG CHEN^4,6, CHING-WEN HUANG^4,5, TSUNG-KUN CHANG^4,6,7, YEN-CHENG CHEN^4,6, CHING-CHUN LI^4,8, YUNG-SUNG YEH^4,9,10, TZU-CHIEH YIN^4,5,11, JAW-YUAN WANG^{4,5,6,12,13,*}

Oncology Research, Vol.32, No.11, pp. 1723-1732, 2024, DOI:10.32604/or.2024.052098 - 16 October 2024

Abstract Background: The pTNM staging system is widely recognized as the most effective prognostic indicator for cancer. The latest update of this staging system introduced a new pathological staging system (ypTNM) for patients receiving neoadjuvant chemoradiotherapy (NACRT). However, whether the prognostic value of the ypTNM staging system for rectal cancer is similar to that of the pTNM staging system remains unclear. This study was conducted to compare the ypTNM and pTNM staging systems in terms of their prognostic value for patients with nonmetastatic rectal cancer undergoing proctectomy. Material and Methods: This study was conducted at a large teaching… More >

BEHROOZ JOHARI^1,2,#,*, MILAD PARVINZAD LEILAN^1,#, MAHMOUD GHARBAVI³, YOUSEF MORTAZAVI¹, ALI SHARAFI², HAMED REZAEEJAM⁴

Oncology Research, Vol.32, No.2, pp. 309-323, 2024, DOI:10.32604/or.2023.043576 - 28 December 2023

Abstract The Myc gene is the essential oncogene in triple-negative breast cancer (TNBC). This study investigates the synergistic effects of combining Myc decoy oligodeoxynucleotides-encapsulated niosomes-selenium hybrid nanocarriers with X-irradiation exposure on the MDA-MB-468 cell line. Decoy and scramble ODNs for Myc transcription factor were designed and synthesized based on promoter sequences of the Bcl2 gene. The nanocarriers were synthesized by loading Myc ODNs and selenium into chitosan (Chi-Se-DEC), which was then encapsulated in niosome-nanocarriers (NISM@Chi-Se-DEC). FT-IR, DLS, FESEM, and hemolysis tests were applied to confirm its characterization and physicochemical properties. Moreover, cellular uptake, cellular toxicity, apoptosis, cell More > Graphic Abstract

Kassem S. Faraj¹, Weslyn D. Bunn², Victoria S. Edmonds², Mark D Tyson¹

Canadian Journal of Urology, Vol.29, No.5, pp. 11284-11290, 2022

Abstract Introduction: A comprehensive analysis on outcomes in the perioperative and pathological setting in patients with a prior diagnosis of prostate cancer has not been performed. The objective of this study is to describe the effect of prior prostate cancer treatment on perioperative and pathological outcomes after cystectomy.
Materials and methods: This was a retrospective review of all male patients who underwent cystectomy at our institution from 01/01/2007-01/01/2020. Patients who were previously diagnosed and treated for prostate cancer were identified and outcomes were assessed.
Results: In 525 male patients, 132 (25.1%) had a diagnosis of prostate cancer prior to… More >

Andrew M. Fang¹, Zachary R. Burns¹, Alexander P. Nocera¹, Rex A. Cardan², Jeffrey W. Nix^1,3, Kristin K. Porter^4,*, Andrew M. McDonald^2,3,*, Soroush Rais-Bahrami^1,3,4

Canadian Journal of Urology, Vol.28, No.5, pp. 10817-10823, 2021

Abstract Introduction: We aim to investigate if the addition of MRI-US fusion biopsy (FB) can aid in radiation planning and alter the boost field in cases of stereotactic body radiation therapy (SBRT) for prostate cancer with a simultaneous integrated boost (SIB) to a magnetic resonance imaging (MRI)-defined intraprostatic lesion.
Materials and methods: Patients undergoing SBRT with SIB for biopsy-proven prostatic adenocarcinoma and a pre-radiation MRI were retrospectively reviewed. 36.25 Gy in 5 fractions was delivered to the entire prostate along with SIB of 40 Gy to an MRI-defined intraprostatic lesion. Demographic, radiation planning details, and post-procedural outcomes were… More >

Heming Lu^*†1, Yuying Wu^‡1, Xu Liu^†, Huixian Huang^†, Hailan Jiang^†, Chaohua Zhu^†, Yuping Man^§, Zhaohong Chen^†, Xianfeng Long^†, Qiang Pang^†, Luxing Peng^†, Xianglong Li^†, Junzhao Gu^†, Shan Deng^†, Ligang Xing^*

Oncology Research, Vol.28, No.9, pp. 929-944, 2020, DOI:10.3727/096504021X16318716607908

Abstract This phase II randomized clinical trial aimed to assess the efficacy and toxicity of Endostar, an antiangiogenesis inhibitor, combined with concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer (LACC). Patients with LACC were randomly assigned to either CCRT plus Endostar (CCRT+E arm) or CCRT alone (CCRT arm). All patients received pelvic intensity-modulated radiation therapy (IMRT) and brachytherapy. Weekly cisplatin was administered concurrently with IMRT. Patients in the CCRT+E arm also received concurrent Endostar every 3 weeks for two cycles. The primary endpoint was progression-free survival (PFS) and acute toxicities. The exploratory endpoint was the impact… More >

Abhinav V. Reddy^1,2, Matthew N. Mills^1,3, Stanley L. Liauw⁴, Sujith Baliga⁵, Charles R. Kersh⁶

Canadian Journal of Urology, Vol.26, No.2, pp. 9743-9745, 2019

Abstract Renal cell carcinoma (RCC) is usually treated with surgery, with or without systemic therapy. For select patients, stereotactic body radiation therapy (SBRT) may be a suitable alternative. Although many reports exist on the successful use of SBRT, very few have described long term outcomes with regard to disease progression and renal function. We report a rare case of a single patient with primary, metastatic, and locally recurrent renal cell carcinoma who was successfully treated with SBRT. The patient has been disease-free for 8 years since treatment, with stable renal function even after two courses of More >

Rachael Sussman^1,2,*, Filipe L.F. Carvalho^1,2,*, Andrew Harbin¹, Choayi Zheng¹, John H. Lynch¹, Lambros Stamatakis², Jonathan Hwang², Stephen B. Williams³, Jim C. Hu⁴, Keith J. Kowalczyk¹

Canadian Journal of Urology, Vol.25, No.5, pp. 9516-9524, 2018

Abstract Introduction: The utility of radical prostatectomy (RP) for locally-advanced prostate cancer remains unknown. Retrospective data has shown equivalent oncologic outcomes compared to radiation therapy (RT). RP may provide local tumor control and prevent secondary interventions from local invasion, and may decrease costs.
Materials and methods: Using SEER-Medicare data from 1995-2011, we identified men with locally-advanced prostate cancer undergoing RP or RT. Rates of post-treatment diagnoses and interventions were identified using ICD-9 and CPT codes. Skeletal related events (SRE), androgen deprivation therapy (ADT) utilization, all-cause mortality, prostate cancer-specific mortality, and costs were compared.
Results: A total of 8367 men… More >